Examining the effectiveness of antipsychotic medication in first-episode psychosis

被引：19

作者：

Taylor, Mark

Cavanagh, Jonathan ^{[1
]}

Hodgson, Richard

Tiihonen, Jari ^{[2
,3
]}

机构：

[1] So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland

[2] Univ Kuopio, Niuvanniemi Hosp, Dept Forens Psychiat, FIN-70211 Kuopio, Finland

[3] Natl Inst Hlth & Welf, Helsinki, Finland

来源：

JOURNAL OF PSYCHOPHARMACOLOGY | 2012年 / 26卷 / S5期

关键词：

Antipsychotic; effectiveness; first-episode psychosis; RANDOMIZED CONTROLLED-TRIAL; ATYPICAL ANTIPSYCHOTICS; 2ND-GENERATION ANTIPSYCHOTICS; SCHIZOAFFECTIVE DISORDER; CHRONIC-SCHIZOPHRENIA; DOUBLE-BLIND; DRUGS; OLANZAPINE; METAANALYSIS; RISPERIDONE;

D O I：

10.1177/0269881112439252

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The regular use of antipsychotic medication is known to improve overall outcomes and diminish risk of relapse, but applying the results of randomised controlled trials (RCTs) into routine clinical practice is not always straightforward. Furthermore, psychiatrists, service users and policy makers can have trouble keeping up with the burgeoning and, at times, conflicting results from research trials, meta-analysis and systematic reviews. In this paper we examine the differences between efficacy and effectiveness trials with regard to antipsychotic medication with a focus on first-episode psychosis, after reviewing the relative contribution of antipsychotic medication to outcomes in schizophrenia.

引用

页码：27 / 32

页数：6

共 50 条

[21] Achieving clinical effectiveness in first-episode psychosis
Fleischhacker, WW
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S103 - S103
[22] Brain volume change in first-episode psychosis: an effect of antipsychotic medication independent of BMI change
Jorgensen, K. N.
Nesvag, R.
Nerland, S.
Morch-Johnsen, L.
Westlye, L. T.
Lange, E. H.
Haukvik, U. K.
Hartberg, C. B.
Melle, I.
Andreassen, O. A.
Agartz, I.
ACTA PSYCHIATRICA SCANDINAVICA, 2017, 135 (02) : 117 - 126
[23] Medication Adherence in a Transdiagnostic First-Episode Psychosis Sample
London, Stephanie M.
Cawkwell, Philip B.
Shinn, Ann K.
JOURNAL OF CLINICAL PSYCHIATRY, 2023, 84 (06)
[24] Medication adherence in first-episode psychosis patients in Singapore
Tan, Chunzhen
Abdin, Edimansyah
Liang, Wilfred
Poon, Ngar Yee
Verma, Swapna
EARLY INTERVENTION IN PSYCHIATRY, 2019, 13 (04) : 780 - 788
[25] Antipsychotic drug effects on brain morphology in first-episode psychosis
Lieberman, JA
Tollefson, GD
Charles, C
Zipursky, R
Sharma, TN
Kahn, RS
Keefe, RSE
Green, AI
Gur, RE
McEvoy, J
Perkins, D
Hamer, RM
Gu, HB
Tohen, M
ARCHIVES OF GENERAL PSYCHIATRY, 2005, 62 (04) : 361 - 370
[26] Early Predictors of Nonadherence to Antipsychotic Therapy in First-Episode Psychosis
Rabinovitch, Mark
Bechard-Evans, Laura
Schmitz, Norbert
Joober, Ridha
Malla, Ashok
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2009, 54 (01): : 28 - 35
[27] Antipsychotic Treatment Effects on the Functional Connectome in First-Episode Psychosis
Sarpal, Deepak
Argyelan, Miklos
Ikuta, Toshikazu
Robinson, Delbert
Malhotra, Anil K.
Szeszko, Philip R.
BIOLOGICAL PSYCHIATRY, 2013, 73 (09) : 298S - 298S
[28] Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis
Riecher-Roessler, A.
Rybakowski, J. K.
Pflueger, M. O.
Beyrau, R.
Kahn, R. S.
Malik, P.
Fleischhacker, W. W.
PSYCHOLOGICAL MEDICINE, 2013, 43 (12) : 2571 - 2582
[29] Antipsychotic Medication During the Critical Period Following Remission From First-Episode Psychosis Less Is More
McGorry, Patrick
Alvarez-Jimenez, Mario
Killackey, Eoin
JAMA PSYCHIATRY, 2013, 70 (09) : 898 - 900
[30] Discontinuing Antipsychotic Medication After Remission from First-Episode Psychosis: A Survey of Psychiatrists' Attitudes in Taiwan
Yen, Ko
Liu, Chen-Chung
Lin, Yi-Ting
Chien, Yi-Ling
Hsieh, Ming H.
Liu, Chih-Min
Hwang, Tzung-Jeng
Liao, Wei-Hsiang
Hwu, Hai-Gwo
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 465 - 475

← 1 2 3 4 5 →